两例由莫德纳新冠疫苗引发的病情得到良好控制的慢性自发性荨麻疹病例。
Two Cases of Well Controlled Chronic Spontaneous Urticaria Triggered by the Moderna COVID-19 Vaccine.
作者信息
Alflen Cylie, Birch Katheryn, Shilian Ryan, Wu Shan Shan, Hostoffer Robert
机构信息
Lake Erie College of Osteopathic Medicine, Erie, Pennsylvania.
Allergy/Immunology Associates Inc., Mayfield Heights, Ohio.
出版信息
Allergy Rhinol (Providence). 2021 Jun 24;12:21526567211026271. doi: 10.1177/21526567211026271. eCollection 2021 Jan-Dec.
Abstract
Chronic spontaneous urticaria (CSU, chronic idiopathic urticaria) is a clinical diagnosis characterized by recurrent urticaria of unknown origin, with or without angioedema, that occurs for six weeks or longer. Management of CSU includes a second-generation H1 antihistamine and/or elimination of exacerbating factors. If initial treatment is unsuccessful, trials of first generation H1 antihistamine, H2 blocking antihistamine, leukotriene-receptor antagonist, anti-inflammatory or immunosuppressive agents may be administered. Exacerbating factors include stress, environmental conditions, medications, physical stimuli, and infections. We report the first two cases of a COVID-19 vaccine triggered relapse of CSU that was previously well controlled on therapy.
摘要
慢性自发性荨麻疹（CSU，慢性特发性荨麻疹）是一种临床诊断，其特征为不明原因的复发性荨麻疹，伴有或不伴有血管性水肿，病程持续六周或更长时间。CSU的治疗包括使用第二代H1抗组胺药和/或消除加重因素。如果初始治疗不成功，可尝试使用第一代H1抗组胺药、H2阻断抗组胺药、白三烯受体拮抗剂、抗炎或免疫抑制剂。加重因素包括压力、环境条件、药物、物理刺激和感染。我们报告了首例两例因新冠病毒疫苗接种导致此前病情得到良好控制的CSU复发的病例。
相似文献
1
Two Cases of Well Controlled Chronic Spontaneous Urticaria Triggered by the Moderna COVID-19 Vaccine.两例由莫德纳新冠疫苗引发的病情得到良好控制的慢性自发性荨麻疹病例。
Allergy Rhinol (Providence). 2021 Jun 24;12:21526567211026271. doi: 10.1177/21526567211026271. eCollection 2021 Jan-Dec.
2
H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study.H1 抗组胺药难治性慢性自发性荨麻疹：比我们想象的更糟糕 - 多中心真实世界 AWARE 研究的初步结果。
Clin Exp Allergy. 2017 May;47(5):684-692. doi: 10.1111/cea.12900. Epub 2017 Mar 2.
3
Relapse or worsening of chronic spontaneous urticaria during SARS-CoV-2 infection and vaccination in children: A telemedicine follow-up.儿童在感染 SARS-CoV-2 及接种疫苗期间慢性自发性荨麻疹复发或恶化：远程医疗随访。
Allergol Immunopathol (Madr). 2022 Sep 22;50(S Pt 2):1-7. doi: 10.15586/aei.v50iSP2.722. eCollection 2022.
4
Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.将组胺 H1 受体拮抗剂比拉斯汀转换为治疗慢性自发性荨麻疹患者的疗效（H1-SWITCH）：一项随机对照试验的研究方案。
Trials. 2020 Jan 6;21(1):23. doi: 10.1186/s13063-019-3878-2.
5
Increased serum soluble vascular endothelial cadherin levels in patients with chronic spontaneous urticaria.慢性自发性荨麻疹患者血清可溶性血管内皮钙黏蛋白水平升高。
Ann Allergy Asthma Immunol. 2017 Jun;118(6):704-709. doi: 10.1016/j.anai.2017.04.013.
6
Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.奥马珠单抗治疗慢性自发性荨麻疹：疗效与安全性专家综述
Expert Opin Biol Ther. 2017 Mar;17(3):375-385. doi: 10.1080/14712598.2017.1285903. Epub 2017 Feb 9.
7
Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.对H1抗组胺药反应不足的慢性自发性荨麻疹的治疗：专家意见
Eur J Dermatol. 2017 Feb 1;27(1):10-19. doi: 10.1684/ejd.2016.2905.
8
Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.抗组胺药抵抗性慢性自发性荨麻疹：AWARE 研究的 1 年数据。
Clin Exp Allergy. 2019 May;49(5):655-662. doi: 10.1111/cea.13309. Epub 2018 Dec 7.
9
Management of chronic spontaneous urticaria: practical parameters.慢性自发性荨麻疹的管理：实用参数
G Ital Dermatol Venereol. 2015 Apr;150(2):237-46. Epub 2015 Feb 25.
10
New-onset chronic spontaneous urticaria post-COVID-19 vaccination-South African case series.新冠病毒疫苗接种后新发慢性自发性荨麻疹——南非病例系列
J Allergy Clin Immunol Glob. 2023 Jul 24;2(4):100154. doi: 10.1016/j.jacig.2023.100154. eCollection 2023 Nov.
引用本文的文献
1
Chronic Spontaneous Urticaria Following COVID-19 Vaccination: A Case Report and Discussion on Allergic Reactions and Vaccine Safety.新冠疫苗接种后慢性自发性荨麻疹：一例报告及关于过敏反应和疫苗安全性的讨论
Cureus. 2023 Sep 7;15(9):e44860. doi: 10.7759/cureus.44860. eCollection 2023 Sep.
2
Clinical Effects of BNT162b2 Vaccine on the Short-Term Course of Chronic Spontaneous Urticaria Patients.BNT162b2疫苗对慢性自发性荨麻疹患者短期病程的临床效果
Indian J Dermatol. 2022 Nov-Dec;67(6):674-681. doi: 10.4103/ijd.ijd_543_22.
3
Can mRNA COVID-19 vaccines induce flares of chronic urticaria?新型冠状病毒mRNA疫苗会引发慢性荨麻疹发作吗？
J Cosmet Dermatol. 2023 Jan;22(1):34-35. doi: 10.1111/jocd.15443. Epub 2022 Oct 25.
4
Chronic spontaneous urticaria following COVID-19 vaccination.新冠病毒疫苗接种后慢性自发性荨麻疹
JAAD Case Rep. 2022 Jul;25:35-38. doi: 10.1016/j.jdcr.2022.05.011. Epub 2022 May 21.
5
Cubital Tunnel Syndrome Temporally after COVID-19 Vaccination.新冠疫苗接种后出现的肘管综合征
Trop Med Infect Dis. 2022 Apr 16;7(4):62. doi: 10.3390/tropicalmed7040062.
6
Chronic Spontaneous Urticaria Triggered by the AstraZeneca/Oxford COVID-19 Vaccine with Achieved Remission: A Case Report.由阿斯利康/牛津新冠疫苗引发并已缓解的慢性自发性荨麻疹：一例报告
Allergy Rhinol (Providence). 2022 Jan 10;13:21526567211068458. doi: 10.1177/21526567211068458. eCollection 2022 Jan-Dec.
7
Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2.接种 BNT162b2 mRNA（辉瑞-生物科技）疫苗后出现慢性自发性荨麻疹，以预防 SARS-CoV-2。
Allergy Asthma Proc. 2022 Jan 1;43(1):30-36. doi: 10.2500/aap.2022.43.210111.
8
Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines.与SARS-CoV-2疫苗相关的皮肤不良反应
J Clin Med. 2021 Nov 16;10(22):5344. doi: 10.3390/jcm10225344.
本文引用的文献
1
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.《对 Moderna COVID-19 疫苗的迟发性局部过敏反应：病例系列》。
JAMA Dermatol. 2021 Jun 1;157(6):716-720. doi: 10.1001/jamadermatol.2021.1214.
2
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.报告的 Moderna 和辉瑞 COVID-19 疫苗接种后皮肤反应：基于登记的 414 例病例研究。
J Am Acad Dermatol. 2021 Jul;85(1):46-55. doi: 10.1016/j.jaad.2021.03.092. Epub 2021 Apr 7.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Chronic Urticaria: An Overview of Treatment and Recent Patents.慢性荨麻疹：治疗概述与近期专利
Recent Pat Inflamm Allergy Drug Discov. 2019;13(1):27-37. doi: 10.2174/1872213X13666190328164931.
5
Chronic Urticaria: Following Practice Guidelines.慢性荨麻疹：遵循实践指南。
Skin Therapy Lett. 2018 May;23(3):1-4.
6
Urticaria and Angioedema: an Update on Classification and Pathogenesis.荨麻疹和血管性水肿：分类和发病机制的更新。
Clin Rev Allergy Immunol. 2018 Feb;54(1):88-101. doi: 10.1007/s12016-017-8628-1.
Zotero 插件